Ligand Expands Captisol License and Supply Agreements with SAGE Therapeutics to Include SAGE-689 September 29, 2015
Revolade® Receives EU Approval as First-in-Class Therapy for Patients with Severe Aplastic Anemia September 2, 2015
FDA Expands Use of Promacta® to Include Treatment of Children Ages 1 and Older with Chronic Immune Thrombocytopenia August 24, 2015
Ligand Enters into Commercial License and Supply Agreement with Sanofi for Captisol-enabled SAR-125844 July 30, 2015
Revolade® Recommended by CHMP for EU Approval to Treat Patients with Severe Aplastic Anemia, a Serious Blood Disorder July 24, 2015
FDA Approves Promacta® for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication June 12, 2015
Ligand Announces Favorable Results From Phase 1b Trial With LGD-6972 in Type 2 Diabetes and Plans to Initiate a Phase 2 Trial June 7, 2015
Ligand Announces New Time for June 7th Investor Presentation and Webcast at the American Diabetes Association 75th Scientific Sessions June 5, 2015
